Tezspire (tezepelumab)

pCPA File Number: 22089

Negotiation Status:

Concluded with an LOI

Indication(s):

Severe asthma, add-on maintenance treatment in adults and adolescents 12 years and older

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CDA-AMC Project Number:

SR0731-000

pCPA Engagement Letter Issued:

2023-06-20

Negotiation Process Concluded:

2023-09-15